Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.44−0.09 (-5.88%)
Close on Nov 17, 2026Market cap $82.73MP/E –Yield –
Black Diamond Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Black Diamond Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$32.84M, down 283.7% year over year. For fiscal 2025 it was $29.61M. The highest annual figure on record is $29.61M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.61M | – |
| FY2024 | Dec 31, 2024 | -$62.30M | – |
| FY2023 | Dec 31, 2023 | -$66.72M | – |
| FY2022 | Dec 31, 2022 | -$85.08M | – |
| FY2021 | Dec 31, 2021 | -$100.15M | – |
| FY2020 | Dec 31, 2020 | -$52.15M | – |
| FY2019 | Dec 31, 2019 | -$24.67M | – |
| FY2018 | Dec 31, 2018 | -$8.45M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.97M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.23M | -119.2% |
| Q4 FY2025 | Dec 31, 2025 | -$6.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.16M | – |
| Q1 FY2025 | Mar 31, 2025 | $53.41M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$21.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.07M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.60M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.48M | – |
| Q2 FY2021 | Jun 30, 2021 | -$25.17M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.77M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.57M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.32M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.31M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.88M | – |
See a number that looks wrong?